These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 3166420)

  • 1. Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.
    Verho M; Korn A; Badian M; Malerczyk V; Waldhäusl W
    Chemotherapy; 1988; 34(3):170-7. PubMed ID: 3166420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Pharmatherapeutica; 1985; 4(6):376-82. PubMed ID: 3866256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.
    Maass L; Malerczyk V; Verho M; Hajdú P; Seeger K; Klesel N
    Infection; 1987; 15(3):202-6. PubMed ID: 3610328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
    Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
    Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of food on the pharmacokinetics of ofloxacin.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Curr Med Res Opin; 1986; 10(3):166-71. PubMed ID: 3460737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability of ofloxacin tablets in comparison to oral solution.
    Malerczyk V; Verho M; Korn A; Rangoonwala R
    Curr Med Res Opin; 1987; 10(8):514-20. PubMed ID: 3479296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ofloxacin after parenteral and oral administration.
    Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1338-42. PubMed ID: 3479046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a single oral dose of ofloxacin in patients with renal failure.
    Nawishy S; Moukhtar I; Sabbour M
    Chemioterapia; 1986 Dec; 5(6):391-3. PubMed ID: 3467875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group].
    Verho M; Dagrosa EE; Malerczyk V
    Infection; 1986; 14 Suppl 1():S47-53. PubMed ID: 3007366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing.
    Badian M; Malerczyk V; Collins JD; Dixon GT; Verho M; Eckert HG
    Chemotherapy; 1988; 34(5):367-73. PubMed ID: 3180904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose related pharmacokinetics of ofloxacin in healthy volunteers.
    Immanuel C; Hemanthkumar AK; Gurumurthy P; Venkatesan P
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1017-22. PubMed ID: 12475149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of ofloxacin in the elderly (65-85 years) with normal renal function after a single oral dose of 200 mg].
    Veyssier P; Fourtillan JB; Modai J; Couet W; Lefebvre MA; Darchis JP; Vincent Du Laurier M; Bryskier A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):596-9. PubMed ID: 3534750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative.
    Malerczyk V; Maass L; Verho M; Hajdú P; Klesel N; Rangoonwala R
    Infection; 1987; 15(3):211-4. PubMed ID: 3610330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ofloxacin on the pharmacokinetics of a single intravenous theophylline dose.
    Al-Turk WA; Shaheen OM; Othman S; Khalaf RM; Awidi AS
    Ther Drug Monit; 1988; 10(2):160-3. PubMed ID: 3164150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers.
    Agarwal S; Solomon WD; Gowda KV; Selvan PS; Ghosh D; Sarkar AK; Chattaraj TK; Pal TK
    Arzneimittelforschung; 2007; 57(10):679-83. PubMed ID: 18074762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary tract excretion of ofloxacin in man.
    Kazmierczak A; Pechinot A; Duez JM; Haas O; Favre JP
    Drugs; 1987; 34 Suppl 1():39-43. PubMed ID: 3481327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and bioavailability of bemoradan, a long-acting inodilator in healthy males.
    Huang SM; Brusser L; Chien SC; Simon D; Smith IL; Abrams LS; Lasseter K
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):62-4. PubMed ID: 8004360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.
    Guay D; Tack K; Flor S
    Int J Clin Pharmacol Res; 1991; 11(5):203-9. PubMed ID: 1814841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.